<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153062">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01939990</url>
  </required_header>
  <id_info>
    <org_study_id>11-0720</org_study_id>
    <nct_id>NCT01939990</nct_id>
  </id_info>
  <brief_title>Safety Study of Nebivolol for COPD Patients</brief_title>
  <official_title>Nebivolol in Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <authority>USA: University of Chicago IRB</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety and effectiveness of the study drug
      Nebivolol, in people who suffer with high blood pressure with Chronic Obstructive Pulmonary
      Disease (COPD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study would be a randomized, placebo-controlled trial of 60 hypertensive patients with
      documented COPD greater than age 40.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>to assess blood pressure control</measure>
    <time_frame>baseline to 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>blood pressure control will be assessed per collection of research data at protocol visits.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to assess pulmonary function tests</measure>
    <time_frame>baseline to 4 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>pulmonary function tests will be assessed at protocol visits</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>High Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Nebivolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A will be given Nebivolol 5 to 10mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group B will be given Placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo looks like the study drug but it does not contain active ingredients.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo is a sugar pill.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebivolol</intervention_name>
    <description>5 to 10mg per day</description>
    <arm_group_label>Nebivolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of high blood pressure and chronic obstructive pulmonary disease
             (COPD)

        Exclusion Criteria:

          -  Asthma; Heart failur;

          -  End stage kidney disease;

          -  acute myocardial infarction,unstable angina, stroke or TIA within the past year;

          -  Females who are pregnant, lactating or women of childbearing potential who are not
             using approved method of contraception.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Bakris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carrie Schlaffer</last_name>
    <phone>773-702-2591</phone>
    <email>cschlaff@medicine.bsd.uchicago.edu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Schlaffer</last_name>
      <phone>773-702-2591</phone>
      <email>cschlaff@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>George L Bakris, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aura.uchicago.edu</url>
    <description>clinical trials at the University of Chicago</description>
  </link>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>September 10, 2013</lastchanged_date>
  <firstreceived_date>January 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nebivolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
